-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2010 to 2023.
- Lineage Cell Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $1.27M, a 0.86% decline year-over-year.
- Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4.64M, a 8.23% increase from 2022.
- Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.29M.
- Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2018 was $298M.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)